Amphion Innovations partner WellGen's theaflavin tea extract gets positive review

A report by the ‘Journal of the International Society of Sports Nutrition’ stated that athletes consuming a proprietary nutraceutical developed by WellGen, a partner of Amphion Innovations (AIM: AMP), demonstrated improved rates of recovery, a reduction in oxidative stress, and reduced muscle soreness following high intensity, anaerobic exercise.

The IP commercialisation company cited the study which commented on the effects of WellGen's theaflavin-enriched black tea extract. These positive effects that were observed are important to both athletes and individuals alike, because they may facilitate increased frequency of exercise and subsequently enhance long-term health and performance, the report said.

"This is good news for athletes and people who exercise for health, because while inflammation is needed to clear the debris from muscles to facilitate muscle regeneration, prolonged inflammation can hinder good health and recovery”, WellGen pesident and chief executive, Roddy Carter M.D. commented. “This study provides exciting data about the impact that WellGen's proprietary black tea extract has on important biomarkers related to both exercise and health".

 The study was designed and carried out by Dr. Shawn M Arent of Rutgers University, and is being published in the peer-reviewed Journal of the International Society of Sports Nutrition this week. Commenting on the study's relevance, Dr Arent said "In the intensely competitive environment of contemporary sport and exercise where fractions of a second determine a winning performance, the ability to increase training frequency and quality is crucial".

In addition to the proprietary nutraceutical’s sports science application, WellGen’s president also noted that the theaflavin-enriched black tea extract also has medical applications. Inflammation and oxidation are important factors in the pathology of diabetes, and WellGen also plans to study the impact of the proprietary extract on important clinical measures in people with diabetes. “More important is that inflammation continues to be at the root of a large number of major diseases, such as diabetes, which still challenge medical professionals despite the broad availability of pharmaceutical interventions”, Carter stated.

WellGen said it plans to commercialize a medical food product for the treatment of diabetes.

Amphion has a significant shareholding in 8 partner companies including WellGen, targeting markets in excess of US$1 billion each with the goal of achieving an exit valuation in excess of $100 million for every partner.

Earlier today, it reported that another partner, Axcess International has launched wireless business credential product Dot Wireless Credential, which encompasses location identification, sensing and control capabilities.

The product was used to help protect US President Barack Obama during last year’s visit to Trinidad.